 |
|
Allergic and Nonallergic Delayed Infusion Reactions During Natalizumab Therapy
Kerstin Hellwig, MD;
Sebastian Schimrigk, MD;
Malte Fischer, MD;
Aiden Haghikia, MD;
Thomas Müller, MD;
Andrew Chan, MD;
Ralf Gold, MD
Arch Neurol. 2008;65(5):656-658.
Background The monoclonal antibody natalizumab is a novel therapeutic option in the treatment of relapsing forms of multiple sclerosis. In general, therapy with natalizumab is well tolerated. Allergic reactions and acute infusion reactions typically occur during or shortly after infusion, with a peak at the second infusion. Delayed infusion reactions resembling serum sickness–type reactions (type III reaction) are commonly reported in other monoclonal antibody therapies (eg, infliximab and rituximab), but are not described yet for natalizumab.
Results Delayed infusion reactions occurred in 4 of 40 relapse-remitting multiple sclerosis patients treated with natalizumab.
Conclusions Clinicians need to consider the occurrence of infusion reactions, with especially delayed reactions occurring more frequently than previously assumed. Our cases illustrate that some of these infusion reactions may be treated effectively with steroids and reduction of the infusion rate. In cases of antibody-mediated reactions, treatment should be stopped immediately.
Author Affiliations: Department of Neurology, St Josef Hospital, Ruhr University Bochum, Bochum, Germany.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
RECURRENT PERICARDITIS DUE TO NATALIZUMAB TREATMENT
Cohen et al.
Neurology 2009;72:1616-1617.
FULL TEXT
Very late delayed-allergic reaction to natalizumab not associated with neutralizing antibodies
Killestein et al.
Mult Scler 2009;15:525-526.
Review: Natalizumab in the treatment of multiple sclerosis
Yaldizli and Putzki
Therapeutic Advances in Neurological Disorders 2009;2:115-128.
ABSTRACT
|
